COMMUNIQUÉS West-GlobeNewswire

Zealand Pharma Announces Financial Results for the First Nine Months of 2025
13/11/2025
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025 With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and [...]
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic
13/11/2025
$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and [...]
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
13/11/2025
New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatment All six patients responded positively to the combination Overall response data [...]
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
13/11/2025
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
13/11/2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
IMU Biosciences announces formation of Scientific Advisory Board
13/11/2025
PRESS RELEASE Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and genetics London, UK, 13 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company [...]
Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.
13/11/2025
KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. ( CSE: MOOD | PINK: DOSEF | FSE: VU70 ) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is [...]
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
12/11/2025
FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME’s 2026 list of America’s Growth Leaders. Presented in [...]
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
12/11/2025
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate of 97.4% based on [...]
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
Anteris Announces Results for the Third Quarter of 2025
12/11/2025
MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to [...]
Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting
13/11/2025
Company to Showcase Cutting-Edge Innovations at Booth #1622 CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the [...]
Caring Brands Announces Pricing of $4,000,000 Million Uplisting to Nasdaq
13/11/2025
FORT PIERCE, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Caring Brands, Inc. (“Caring Brands” or the “Company”), a wellness consumer products company offering several over-the-counter (OTC) and cosmetic consumer products, [...]
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
13/11/2025
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing [...]
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
12/11/2025
Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform Realigned pipeline [...]
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
12/11/2025
● Q3 Revenue of $8.8 million ● Q3 Cash Collections of $10.0 million ● Q3 Thyroid test volume up 12% year-over-year to record levels ● Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ, [...]
Ascendis Pharma Reports Third Quarter 2025 Financial Results
12/11/2025
– Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ® – Q3 2025 operating profit of €11.0 million – TransCon ® CNP (navepegritide) under FDA Priority Review for the treatment of children [...]
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
12/11/2025
Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET [...]
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- [...]

Pages